Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Allergy and Asthma Reports
Erschienen in: Current Allergy and Asthma Reports 1/2010

01.01.2010

Update on Infection and Antibiotics in Asthma

verfasst von: Donald R. Rollins, David A. Beuther, Richard J. Martin

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Asthma pathogenesis seems to be a result of a complex mixture of genetic and environmental influences. There is evidence that Mycoplasma pneumoniae and Chlamydophila pneumoniae (formerly known as Chlamydia pneumoniae) play a role in promoting airway inflammation that could contribute to the onset and clinical course of asthma. Evidence also indicates that when antimicrobial therapy can eradicate or suppress these organisms, it may be possible to alter the course of the disease. Certain macrolide antibiotics have been shown to improve control of asthma symptoms and lung function in patients diagnosed with acute C. pneumoniae or M. pneumoniae infection. Positive polymerase chain reaction studies for C. pneumoniae or M. pneumoniae are needed to select asthma patients for chronic treatment. Macrolide antibiotics may also have independent anti-inflammatory activity that may be useful in the management of asthma and other inflammatory diseases.
Literatur
1.
Biscardi S, Lorrot M, Marc E, et al.: Mycoplasma pneumoniae and asthma in children. Clin Infect Dis 2004, 38:1341–1346.CrossRefPubMed
2.
Bisgaard H, Hermansen MN, Buchvald F, et al.: Childhood asthma after bacterial colonization of the airway in neonates. N Engl J Med 2007, 357:1487–1495.CrossRefPubMed
3.
Emre U, Sokolovskaya N, Roblin PM, et al.: Detection of anti-Chlamydia pneumoniae IgE in children with reactive airway disease. J Infect Dis 1995, 172:265–267.PubMed
4.
Gil JC, Cedillo RL, Mayagoitia BG, et al.: Isolation of Mycoplasma pneumoniae from asthmatic patients. Ann Allergy 1993, 70:23–25.PubMed
5.
Kraft M, Cassell GH, Pak J, et al.: Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest 2002, 121:1782–1788.CrossRefPubMed
6.
Martin RJ, Kraft M, Chu HW, et al.: A link between chronic asthma and chronic infection. J Allergy Clin Immunol 2001, 107:595–601.CrossRefPubMed
7.
Blasi F, Johnston SL: The role of antibiotics in asthma. Int J Antimicrob Agents 2007, 29:485–493.CrossRefPubMed
8.
Johnston SL, Martin RJ: Chlamydophila pneumoniae and Mycoplasma pneumoniae: a role in asthma pathogenesis? Am J Respir Crit Care Med 2005, 172:1078–1089.CrossRefPubMed
9.
•• Sutherland ER, Martin RJ: Asthma and atypical bacterial infection. Chest 2007, 132:1962–1966. This is an excellent review of important research linking M. pneumoniae and C. pneumoniae to persistent asthma pathogeneis and concerning the benefit of treatment with macrolide antibiotics.CrossRefPubMed
10.
Bradding P, Walls AF, Holgate ST: The role of the mast cell in the pathophysiology of asthma. J Allergy Clin Immunol 2006, 117:1277–1284.CrossRefPubMed
11.
Hanania NA: Targeting airway inflammation in asthma: current and future therapies. Chest 2008, 133:989–998.CrossRefPubMed
12.
Bisgaard H, Flores-Nunez A, Goh A, et al.: Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children. Am J Respir Crit Care Med 2008, 178:854–860.CrossRefPubMed
13.
Jackson DJ, Gangnon RE, Evans MD, et al.: Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med 2008, 178:667–672.CrossRefPubMed
14.
Wos M, Sanak M, Soja J, et al.: The presence of rhinovirus in lower airways of patients with bronchial asthma. Am J Respir Crit Care Med 2008, 177:1082–1089.CrossRefPubMed
15.
Caudri D, Wijga A, Scholtens S, et al.: Early daycare is associated with an increase in airway symptoms in early childhood but is no protection against asthma or atopy at 8 years. Am J Respir Crit Care Med 2009, 180:491–498.CrossRefPubMed
16.
Wark PA, Johnston SL, Bucchieri F, et al.: Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 2005, 201:937–947.CrossRefPubMed
17.
Esposito S, Principi N: Asthma in children: are chlamydia or mycoplasma involved? Paediatr Drugs 2001, 3:159–168.CrossRefPubMed
18.
Berkovich S, Millian SJ, Snyder RD: The association of viral and mycoplasma infections with recurrence of wheezing in the asthmatic child. Ann Allergy 1970, 28:43–49.PubMed
19.
Denlinger LC, Shi L, Guadarrama A, et al.: Attenuated P2X7 pore function as a risk factor for virus-induced loss of asthma control. Am J Respir Crit Care Med 2009, 179:265–270.CrossRefPubMed
20.
Baseman JB, Tully JG: Mycoplasmas: sophisticated, reemerging, and burdened by their notoriety. Emerg Infect Dis 1997, 3:21–32.CrossRefPubMed
21.
Andersen P: Pathogenesis of lower respiratory tract infections due to Chlamydia, Mycoplasma, Legionella and viruses. Thorax 1998, 53:302–307.CrossRefPubMed
22.
Kraft M, Cassell GH, Henson JE, et al.: Detection of Mycoplasma pneumoniae in the airways of adults with chronic asthma. Am J Respir Crit Care Med 1998, 158:998–1001.PubMed
23.
Chu HW, Honour JM, Rawlinson CA, et al.: Effects of respiratory Mycoplasma pneumoniae infection on allergen-induced bronchial hyperresponsiveness and lung inflammation in mice. Infect Immun 2003, 71:1520–1526.CrossRefPubMed
24.
Chu HW, Rino JG, Wexler RB, et al.: Mycoplasma pneumoniae infection increases airway collagen deposition in a murine model of allergic airway inflammation. Am J Physiol Lung Cell Mol Physiol 2005, 289:L125–L133.CrossRefPubMed
25.
Gonzales R, Steiner JF, Sande MA: Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA 1997, 278:901–904.CrossRefPubMed
26.
McCaig LF, Hughes JM: Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA 1995, 273:214–219.CrossRefPubMed
27.
Hirschmann JV: Antibiotics for common respiratory tract infections in adults. Arch Intern Med 2002, 162:256–264.CrossRefPubMed
28.
Graham VA, Milton AF, Knowles GK, et al.: Routine antibiotics in hospital management of acute asthma. Lancet 1982, 1:418–420.CrossRefPubMed
29.
Shapiro GG, Eggleston PA, Pierson WE, et al.: Double-blind study of the effectiveness of a broad spectrum antibiotic in status asthmaticus. Pediatrics 1974, 53:867–872.PubMed
30.
Johnston SL, Blasi F, Black PN, et al.: The effect of telithromycin in acute exacerbations of asthma. N Engl J Med 2006, 354:1589–1600.CrossRefPubMed
31.
•• Krishnan JA, Nowak R, Davis SQ, et al.: Anti-inflammatory treatment after discharge home from the emergency department in adults with acute asthma. Proc Am Thorac Soc 2009, 6:380–385. This is a review of 37 controlled trials of outpatient treatment of acute asthma exacerbations comparing different treatment programs. It includes a review of the study by Johnston et al. [30].CrossRefPubMed
32.
Michels N, Chu HW, LaFasto S, et al.: Mast cells mediate Mycoplasma pneumoniae clearance after acute infection. Am J Respir Crit Care Med 2009 (in press).
33.
Itkin IH, Menzel ML: The use of macrolide antibiotic substances in the treatment of asthma. J Allergy 1970, 45:146–162.CrossRefPubMed
34.
Jaffe A, Bush A: Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol 2001, 31:464–473.CrossRefPubMed
35.
Garey KW, Rubinstein I, Gotfried MH, et al.: Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. Chest 2000, 118:1826–1827.CrossRefPubMed
36.
Yalcin E, Kiper N, Ozcelik U, et al.: Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. J Clin Pharm Ther 2006, 31:49–55.CrossRefPubMed
37.
Tahan F, Ozcan A, Koc N: Clarithromycin in the treatment of RSV bronchiolitis: a double-blind, randomised, placebo-controlled trial. Eur Respir J 2007, 29:91–97.CrossRefPubMed
38.
Yamada T, Fujieda S, Mori S, et al.: Macrolide treatment decreased the size of nasal polyps and IL-8 levels in nasal lavage. Am J Rhinol 2000, 14:143–148.CrossRefPubMed
39.
Simpson JL, Powell H, Boyle MJ, et al.: Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008, 177:148–155.CrossRefPubMed
40.
Gibson PG, Simpson JL, Saltos N: Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 2001, 119:1329–1336.CrossRefPubMed
41.
Labro MT, Abdelghaffar H: Immunomodulation by macrolide antibiotics. J Chemother 2001, 13:3–8.PubMed
42.
Kawasaki S, Takizawa H, Ohtoshi T, et al.: Roxithromycin inhibits cytokine production by and neutrophil attachment to human bronchial epithelial cells in vitro. Antimicrob Agents Chemother 1998, 42:1499–1502.PubMed
43.
Takizawa H, Desaki M, Ohtoshi T, et al.: Erythromycin suppresses interleukin 6 expression by human bronchial epithelial cells: a potential mechanism of its anti-inflammatory action. Biochem Biophys Res Commun 1995, 210:781–786.CrossRefPubMed
44.
Fost DA, Leung DY, Martin RJ, et al.: Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy. J Allergy Clin Immunol 1999, 103:1031–1035.CrossRefPubMed
45.
Black PN: Anti-inflammatory effects of macrolide antibiotics. Eur Respir J 1997, 10:971–972.CrossRefPubMed
46.
Periti P, Mazzei T, Mini E, et al.: Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992, 23:106–131.CrossRefPubMed
47.
Siracusa A, Brugnami G, Fiordi T, et al.: Troleandomycin in the treatment of difficult asthma. J Allergy Clin Immunol 1993, 92:677–682.CrossRefPubMed
48.
Garey KW, Alwani A, Danziger LH, et al.: Tissue reparative effects of macrolide antibiotics in chronic inflammatory sinopulmonary diseases. Chest 2003, 123:261–265.CrossRefPubMed
49.
Kroegel C, Rodel J, Mock B: Chlamydia pneumoniae, clarithromycin, and severe asthma. Chest 2001, 120:1035–1036.CrossRefPubMed
50.
Kamada AK, Hill MR, Ikle DN, et al.: Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. J Allergy Clin Immunol 1993, 91:873–882.CrossRefPubMed
51.
Nelson HS, Hamilos DL, Corsello PR, et al.: A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. Am Rev Respir Dis 1993, 147:398–404.PubMed
52.
Ekici A, Ekici M, Erdemoglu AK: Effect of azithromycin on the severity of bronchial hyperresponsiveness in patients with mild asthma. J Asthma 2002, 39:181–185.CrossRefPubMed
53.
Shimizu T, Kato M, Mochizuki H, et al.: Roxithromycin reduces the degree of bronchial hyperresponsiveness in children with asthma. Chest 1994, 106:458–461.CrossRefPubMed
54.
Kamoi H, Kurihara N, Fujiwara H, et al.: The macrolide antibacterial roxithromycin reduces bronchial hyperresponsiveness and superoxide anion production by polymorphonuclear leukocytes in patients with asthma. J Asthma 1995, 32:191–197.CrossRefPubMed
55.
Amayasu H, Yoshida S, Ebana S, et al.: Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann Allergy Asthma Immunol 2000, 84:594–598.PubMedCrossRef
Metadaten
Titel
Update on Infection and Antibiotics in Asthma
verfasst von
Donald R. Rollins
David A. Beuther
Richard J. Martin
Publikationsdatum
01.01.2010
Verlag
Current Science Inc.
Erschienen in
Current Allergy and Asthma Reports / Ausgabe 1/2010
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-009-0086-2

Weitere Artikel der Ausgabe 1/2010

Current Allergy and Asthma Reports 1/2010 Zur Ausgabe

OriginalPaper

The Role of Regulatory T Cells in Respiratory Infections and Allergy and Asthma

Clinical Trial Report

Immunosuppression Medication as an Approach to Treat Chronic Idiopathic Urticaria in Children

OriginalPaper

Lyme Disease: A Review

OriginalPaper

Pathogenesis of Allergic Airway Inflammation

OriginalPaper

Chronic Helminth Infections Protect Against Allergic Diseases by Active Regulatory Processes

OriginalPaper

Anaphylaxis and Mast Cell Disease: What Is the Risk?

Neu im Fachgebiet HNO

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Eingreifen von Umstehenden rettet vor Erstickungstod

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Real-World-Daten sprechen eher für Dupilumab als für Op.

14.05.2024 Rhinosinusitis Nachrichten

Zur Behandlung schwerer Formen der chronischen Rhinosinusitis mit Nasenpolypen (CRSwNP) stehen seit Kurzem verschiedene Behandlungsmethoden zur Verfügung, darunter Biologika, wie Dupilumab, und die endoskopische Sinuschirurgie (ESS). Beim Vergleich der beiden Therapieoptionen war Dupilumab leicht im Vorteil.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise